Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00475917 · ClinicalTrials.gov registry record · Phase 1
A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies
A Phase 1 study, sponsored by Exelixis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00475917 is a Phase 1 study that was terminated before completion, run by Exelixis. The registered enrollment target is 28 participants.
The verdict
NCT00475917, a Phase 1 study, was terminated before completion, sponsored by Exelixis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to determine a safe dose of XL844 in combination with gemcitabine, how often it should be taken, and how well people with cancer tolerate the combination of gemcitabine and XL844.
Interventions
- DRUG Gemcitabine
- DRUG XL844
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00475917
The ClinicalTrials.gov registry entry for NCT00475917 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00475917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00475917 about?
NCT00475917 is a clinical study titled "A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies". The purpose of this study is to determine a safe dose of XL844 in combination with gemcitabine, how often it should be taken, and how well people with cancer tolerate the combination of gemcitabine and XL844.
What is the current status of trial NCT00475917?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2007-05. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00475917?
The interventions under investigation include: Gemcitabine (DRUG), XL844 (DRUG).
Who is sponsoring clinical trial NCT00475917?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.